This study investigates stereotactic adaptive radiation therapy for pancreatic cancer. The condition is borderline resectable, locally advanced, or medically inoperable pancreatic adenocarcinoma.
The study evaluates the effects of this therapy on gastrointestinal toxicity, overall survival, local control, quality of life, and workflow metrics.
- Who can participate: Adults aged 18 and older with confirmed pancreatic adenocarcinoma that is borderline resectable, locally advanced, or medically inoperable may participate. Participants must have a good performance status and have received prior chemotherapy.
- Study details: Participants will receive stereotactic adaptive radiation therapy. A placebo is not used in this study. The therapy is designed to manage pancreatic cancer with specific radiation doses.